Jessica C Hassel

List of Publications by Year
in descending order

171	39,443	53939 47	7627 156
papers	citations	h-index	g-index

177	177	177	39262
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	1.3	28
2	Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. , 2022, 10, e003198.		21
3	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers, 2022, 14, 518.	1.7	6
4	TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. Cancers, 2022, 14, 1215.	1.7	8
5	Targeted Therapy for Melanomas Without BRAF V600 Mutations. Current Treatment Options in Oncology, 2022, 23, 831-842.	1.3	8
6	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers, 2022, 14, 1804.	1.7	4
7	Tebentafusp for the treatment of metastatic uveal melanoma. Future Oncology, 2022, 18, 1303-1311.	1.1	1
8	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. European Journal of Cancer, 2022, 166, 24-32.	1.3	10
9	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. European Journal of Cancer, 2022, 166, 60-72.	1.3	7
10	Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. Cancer Immunology, Immunotherapy, 2022, 71, 2051-2056.	2.0	10
11	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). OncoImmunology, 2022, 11, 2066609.	2.1	13
12	Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy. Strahlentherapie Und Onkologie, 2022, 198, 884-891.	1.0	2
13	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	1.2	2
14	Four cases of erysipelasâ€like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors. JDDG - Journal of the German Society of Dermatology, 2021, 19, 598-602.	0.4	1
15	Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. OncoImmunology, 2021, 10, 1926762.	2.1	32
16	Generalized perforating granuloma annulare: a case report. JDDG - Journal of the German Society of Dermatology, 2021, 19, 585-587.	0.4	1
17	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. Cancers, 2021, 13, 1019.	1.7	12
18	Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. Life, 2021, 11, 269.	1.1	7

#	Article	IF	Citations
19	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials, 2021, 22, 294.	0.7	1
20	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	1.3	40
21	Multiple alopecic patches in the hairy scalp area of a 28â€yearâ€old female patient. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1222-1224.	0.4	0
22	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
23	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer, 2021, 149, 37-48.	1.3	12
24	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy â€“ A multicentre study of 90 patients from the German Dermatooncology Group. European Journal of Cancer, 2021, 149, 1-10.	1.3	10
25	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	1.3	2
26	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	1.7	8
27	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	1.3	15
28	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers, 2021, 13, 2319.	1.7	15
29	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	5.1	224
30	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. European Journal of Cancer, 2021, 152, 139-154.	1.3	13
31	Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. European Journal of Cancer, 2021, 152, 41-48.	1.3	18
32	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq0 0 0 rgBT /Overlock 10 T	52	
33	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers, 2021, 13, 3359.	1.7	18
34	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. Cancer Research, 2021, 81, CT002-CT002.	0.4	10
35	Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Research, 2021, 11, 89.	1.1	15
36	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	13.9	376

#	Article	IF	Citations
37	Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab. Immunotherapy, 2021, 13, 1079-1083.	1.0	2
38	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1932-1943.	3.3	17
39	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
40	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. Cancers, 2021, 13, 5170.	1.7	1
41	Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma. British Journal of Cancer, 2021, , .	2.9	1
42	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition â€" A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 2021, 11, 765608.	1.3	10
43	546â€...Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). , 2021, 9, A576-A576.		3
44	Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma. Life, 2021, 11, 1318.	1.1	7
45	549â€...An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion. , 2021, 9, A579-A579.		2
46	538â€...Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2
47	Cerebral metastases of a dermatofibrosarcoma protuberans. JDDG - Journal of the German Society of Dermatology, 2020, 18, 143-145.	0.4	0
48	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell, 2020, 182, 1252-1270.e34.	13.5	259
49	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	0.8	119
50	Positron Emission Tomography in Merkel Cell Carcinoma. Cancers, 2020, 12, 2897.	1.7	9
51	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
52	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. European Journal of Cancer, 2020, 138, 125-132.	1.3	44
53	Melanoma brain metastases â€" Interdisciplinary management recommendations 2020. Cancer Treatment Reviews, 2020, 89, 102083.	3.4	52
54	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	13.7	526

#	Article	IF	Citations
55	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. Cancers, 2020, 12, 3004.	1.7	3
56	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. Frontiers in Oncology, 2020, 10, 592796.	1.3	10
57	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	1.1	2
58	Human innate immune cell crosstalk induces melanoma cell senescence. OncoImmunology, 2020, 9, 1808424.	2.1	5
59	Pleomorphic dermal sarcoma with cerebral metastasis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 886-888.	0.4	0
60	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2020, 395, 1558-1568.	6.3	188
61	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. Journal of Clinical Medicine, 2020, 9, 1438.	1.0	11
62	Side effect management during immune checkpoint blockade using CTLAâ€4 and PDâ€1 antibodies for metastatic melanoma â€“ an update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 582-609.	0.4	24
63	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. American Journal of Hematology, 2020, 95, 1158-1169.	2.0	25
64	â€œUniCARâ€•modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Scientific Reports, 2020, 10, 2141.	1.6	62
65	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2257-2267.	3.2	39
66	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunology, Immunotherapy, 2020, 69, 1823-1832.	2.0	19
67	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
68	The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones. Clinical Cancer Research, 2020, 26, 4289-4301.	3.2	46
69	Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.		0
70	Clinical significance of signs of autoimmune colitis in ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy, 2019, 11, 667-676.	1.0	41
71	5-year results for pembrolizumab treatment of advanced melanoma. Lancet Oncology, The, 2019, 20, 1187-1189.	5.1	5
72	Immunotherapies for the Treatment of Uveal Melanomaâ€”History and Future. Cancers, 2019, 11, 1048.	1.7	56

#	Article	IF	Citations
73	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
74	Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	0.8	83
75	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600ÂE/Kâ€“mutant advanced or metastatic melanoma. European Journal of Cancer, 2019, 109, 61-69.	1.3	63
76	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open, 2019, 4, e000491.	2.0	140
77	Prophylaxis and Management of Skin Toxicities. Breast Care, 2019, 14, 72-77.	0.8	15
78	Susceptibilityâ€weighted imaging in malignant melanoma brain metastasis. Journal of Magnetic Resonance Imaging, 2019, 50, 1251-1259.	1.9	11
79	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. European Journal of Cancer, 2019, 110, 11-20.	1.3	44
80	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	2.0	35
81	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	0.6	43
82	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. Cancer Immunology, Immunotherapy, 2019, 68, 297-303.	2.0	45
83	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	3.4	295
84	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	5.1	183
85	Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 917-924.	2.0	22
86	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1289-1296.	3.3	90
87	STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-Î±. Melanoma Research, 2018, 28, 204-210.	0.6	8
88	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patternsâ€"Results of a non-interventional study of the DeCOG. European Journal of Cancer, 2018, 96, 34-43.	1.3	97
89	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	2.9	34
90	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine, 2018, 7, 95-104.	1.3	16

#	Article	IF	Citations
91	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunology, Immunotherapy, 2018, 67, 175-182.	2.0	90
92	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 376-383.	3.3	160
93	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	0.8	431
94	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics, 2018, 8, 76.	1.3	23
95	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.3	21
96	Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. European Journal of Cancer, 2018, 104, 239-242.	1.3	43
97	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology, 2018, 4, 1721.	3.4	1,625
98	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatmentâ€"A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology, 2018, 9, 1474.	2.2	174
99	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology, Immunotherapy, 2018, 67, 1261-1270.	2.0	22
100	Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. PLoS ONE, 2018, 13, e0193946.	1.1	27
101	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. European Journal of Cancer, 2017, 75, 24-32.	1.3	162
102	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treatment Reviews, 2017, 57, 36-49.	3.4	257
103	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with <u>Ta</u>dalafil in patients with metastatic Melanoma (TaMe). OncoImmunology, 2017, 6, e1326440.	2.1	74
104	Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. Journal of Immunotherapy, 2017, 40, 282-285.	1.2	28
105	Liquid Biopsy: Value for Melanoma Therapy?. Oncology Research and Treatment, 2017, 40, 430-434.	0.8	9
106	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Research, 2017, 27, 321-325.	0.6	46
107	Antiâ€PDâ€1 antibodies in metastatic uveal melanoma: a treatment option?. Cancer Medicine, 2017, 6, 1581-1586.	1.3	26
108	The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. Journal of Investigative Dermatology, 2017, 137, 261-264.	0.3	9

#	Article	IF	Citations
109	PD-1 Antibody-induced Guillain-BarrÃ© Syndrome in a Patient with Metastatic Melanoma. Acta Dermato-Venereologica, 2017, 97, 395-396.	0.6	39
110	Bone Formation in Cutaneous Nodules on the Leg: A Quiz. Acta Dermato-Venereologica, 2017, 97, 1263-1264.	0.6	0
111	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 3815-3822.	0.8	244
112	Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Hellenic Journal of Nuclear Medicine, 2017, 20, 251-253.	0.2	1
113	Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinoma. Journal of Cutaneous Pathology, 2016, 43, 367-371.	0.7	3
114	Rasterâ€scanned intensityâ€controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. Head and Neck, 2016, 38, E1445-51.	0.9	13
115	18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Clinical Nuclear Medicine, 2016, 41, 156-158.	0.7	5
116	Exanthematous cutaneous spread of metastatic urothelial carcinoma in a 69â€yearâ€old man. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1300-1302.	0.4	0
117	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
118	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 210-225.	1.3	490
119	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 2016, 60, 190-209.	1.3	546
120	Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncology, The, 2016, 17, 1471-1472.	5.1	20
121	Immunotherapy of Melanoma. Oncology Research and Treatment, 2016, 39, 369-376.	0.8	14
122	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	13.9	1,140
123	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	2.1	75
124	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Research, 2016, 6, 61.	1.1	29
125	Management of side effects of immune checkpoint blockade by antiâ€CTLAâ€4 and antiâ€PDâ€1 antibodies in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-681.	0.4	63
126	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	13.7	1,243

#	Article	IF	Citations
127	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	3.2	459
128	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	3.4	534
129	Vemurafenib and ipilimumab: A promising combination? Results of a case series. OncoImmunology, 2016, 5, e1101207.	2.1	17
130	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Reviews, 2016, 45, 7-18.	3.4	354
131	Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Annals of Oncology, 2016, 27, 1353-1354.	0.6	13
132	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. Oncotarget, 2016, 7, 36130-36137.	0.8	12
133	Two cases of intralymphatic histiocytosis following hip replacement. JDDG - Journal of the German Society of Dermatology, 2015, 13, 700-702.	0.4	2
134	In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: A feasibility study. Journal of Magnetic Resonance Imaging, 2015, 41, 1405-1412.	1.9	4
135	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. Future Oncology, 2015, 11, 591-606.	1.1	16
136	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	5.7	143
137	RAS Mutations in Benign Epithelial Tumors Associated with BRAF Inhibitor Treatment of Melanoma. Journal of Investigative Dermatology, 2015, 135, 636-639.	0.3	6
138	Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. New England Journal of Medicine, 2015, 372, 320-330.	13.9	4,795
139	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 386-396.	3.3	130
140	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	5.1	2,353
141	Solitary, Well-Circumscribed, Depressed Palmar Lesion. American Journal of Dermatopathology, 2015, 37, 166.	0.3	1
142	Solitary, Well-Circumscribed Depressed Palmar Lesion. American Journal of Dermatopathology, 2015, 37, 156.	0.3	0
143	Primary melanoma of the prostate: case report and review of the literature. BMC Urology, 2015, 15, 68.	0.6	14
144	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015, 350, 207-211.	6.0	2,275

#	Article	IF	Citations
145	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 2014, 4, 94-109.	7.7	782
146	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹I-BA52. Journal of Nuclear Medicine, 2014, 55, 9-14.	2.8	48
147	Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds. PLoS ONE, 2014, 9, e95723.	1.1	15
148	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 2014, 50, 406-410.	1.3	26
149	Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlentherapie Und Onkologie, 2014, 190, 1080-1081.	1.0	15
150	Comparison of molecular abnormalities in vulvar and vaginal melanomas. Modern Pathology, 2014, 27, 1386-1393.	2.9	70
151	Axillary accessory breast tissue â€“ case report and review of literature. JDDG - Journal of the German Society of Dermatology, 2014, 12, 499-500.	0.4	3
152	Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus. Journal of Investigative Dermatology, 2013, 133, 1034-1042.	0.3	34
153	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. Academic Radiology, 2013, 20, 423-429.	1.3	6
154	Varicella-Like Cutaneous Toxoplasmosis in a Patient with Aplastic Anemia. Journal of Clinical Microbiology, 2013, 51, 1341-1344.	1.8	7
155	Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma. Experimental Dermatology, 2013, 22, 757-759.	1.4	11
156	Necrolytic Migratory Erythema in a Patient with Neuroendocrine Carcinoma. Internal Medicine, 2013, 52, 151-152.	0.3	1
157	Malignant Melanoma S3-Guideline â€œDiagnosis, Therapy and Follow-up of Melanomaâ€• JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.4	122
158	Compression Treatment of Ear Keloids by a Modified Oyster Splint Technique. , 2013, , 499-505.		0
159	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	13.9	1,976
160	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. Journal of Clinical Oncology, 2012, 30, LBA8509-LBA8509.	0.8	14
161	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. Journal of Clinical Oncology, 2012, 30, e19031-e19031.	0.8	0
162	Psychosomatic or allergic symptoms? High levels for somatization in patients with drug intolerance. Journal of Dermatology, 2011, 38, 959-965.	0.6	22

#	Article	IF	Citations
163	Promising Results from a Pilot Study on Compression Treatment of Ear Keloids. Journal of Cutaneous Medicine and Surgery, 2011, 15, 130-136.	0.6	17
164	Phenol Chemical Matricectomy Is Less Painful, with Shorter Recovery Times but Higher Recurrence Rates, Than Surgical Matricectomy: A Patient's View. Dermatologic Surgery, 2010, 36, 1294-1299.	0.4	21
165	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	13.9	13,065
166	Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. Clinical Cancer Research, 2009, 15, 5208-5215.	3.2	168
167	Predicting tooth color from facial features and gender: Results from a white elderly cohort. Journal of Prosthetic Dentistry, 2008, 99, 101-106.	1.1	22
168	STAT5 contributes to antiapoptosis in melanoma. Melanoma Research, 2008, 18, 378-385.	0.6	34
169	Treatment of Ear Keloids by Compression, Using a Modified Oyster-Splint Technique. Dermatologic Surgery, 2007, 33, 208-212.	0.4	14
170	STAT5 Contributes to Interferon Resistance of Melanoma Cells. Current Biology, 2005, 15, 1629-1639.	1.8	56
171	Serological Immunomarkers in Cutaneous T Cell Lymphoma. Dermatology, 2004, 209, 296-300.	0.9	30